...
首页> 外文期刊>African Journal of Biotechnology >Effects of early angioplasty after fibrinolysis on prognosis of patients with ST-segment elevation acute myocardial infarction
【24h】

Effects of early angioplasty after fibrinolysis on prognosis of patients with ST-segment elevation acute myocardial infarction

机译:纤溶后早期血管成形术对ST段抬高急性心肌梗死患者预后的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Patients having myocardial infarction with ST-segment elevation often cannot undergo timely primary percutaneous coronary intervention (PCI) and therefore receive fibrinolysis. The role and optimal timing of routine PCI after fibrinolysis have not been established.?368?high-risk patients who had myocardial infarction with ST-segment elevation and fibrinolytic therapy were divided into early PCI group (n = 162), PCI within 6 h after fibrinolysis and standard treatment group (n = 206), and single drug therapy or PCI after one day of fibrinolysis. All patients received aspirin, tenecteplase, urokinase, pro-urokinase, streptokinase, rt-pa, Tnk and heparin, while enoxaparin or clopidogrel was recommended. The MACE was the composite of death, reinfarction, recurrent ischemia, new or worsening congestive heart failure, or cardiogenic shock during the in-hospital periods. Cardiac catheterization and PCI was performed for 34% of the patients in the standard-treatment group and 100% of the patients in the early-PCI group. A follow-up evaluation at in-hospital days was completed for all patients. The major adverse cardiac event occurred in 3.1% of the patients in the early-PCI group and in 17.0% of the patients in the standard-treatment group. There were no significant differences between the groups in the incidence of major bleeding. Among high-risk patients who had myocardial infarction with ST-segment elevation and who were treated with fibrinolysis, early PCI within 6 h after fibrinolysis decreased mortality in hospitals than standard treatment.
机译:患有ST段抬高的心肌梗死的患者通常无法及时接受原发性经皮冠状动脉介入治疗(PCI),因此需要接受纤溶治疗。尚未确定纤溶后常规PCI的作用和最佳时机。将368例ST段抬高并纤溶治疗的心肌梗死高危患者分为早期PCI组(n = 162)和6 h内PCI纤维蛋白溶解和标准治疗组(n = 206)后,以及纤维蛋白溶解一天后进行单药治疗或PCI。所有患者均接受阿司匹林,替奈普酶,尿激酶,尿激酶原,链激酶,rt-pa,Tnk和肝素,而推荐使用依诺肝素或氯吡格雷。 MACE是住院期间死亡,再梗塞,复发性缺血,新发或恶化的充血性心力衰竭或心源性休克的综合。在标准治疗组中,有34%的患者进行了心脏导管和PCI,在早期PCI组中,有100%的患者进行了心脏导管和PCI。所有患者在住院日的随访评估均已完成。在PCI早期组中,主要的不良心脏事件发生在3.1%的患者中,在标准治疗组中发生在17.0%的患者中。两组之间的大出血发生率无显着差异。在患有ST段抬高的心肌梗死并接受纤溶治疗的高危患者中,纤溶后6小时内早期PCI降低了医院的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号